232 filings
Page 6 of 12
8-K
0unuv4
14 Aug 19
Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431
12:00am
8-K
kvand59o
7 Aug 19
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
1:11pm
8-K
76vf4 k2htpiiqvw
31 Jul 19
Other Events
1:41pm
8-K
pe5hy4n 734yraj
30 Jul 19
Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH
4:49pm
8-K
0qfbsisdc
23 Jul 19
Amendments to Articles of Incorporation or Bylaws
8:00am
8-K
qn10 u49euqpk
20 Jun 19
ContraVir Pharmaceuticals, Inc. Announces Pricing of $15.6 Million Public Offering
4:30pm
8-K
v7t4p gkgr620
17 Jun 19
Compelling Positive Results Reported from Human Liver Experiments with ContraVir Pharmaceuticals’ NASH Drug Candidate
11:18am
8-K/A
sruqb gzegp7h00gplqc
12 Jun 19
Other Events
10:56am
8-K
gt5klft
11 Jun 19
ContraVir Pharmaceuticals Announces Publication of CRV431 Data from
12:33pm
8-K
v4pm5 mcl5v
11 Jun 19
Regulation FD Disclosure
9:31am
8-K
e5vemarh
6 Jun 19
ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis
11:28am
8-K
vvod7p80
31 May 19
ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split
8:30am
8-K
c9c407gt54lf6imix
8 May 19
Amendments to Articles of Incorporation or Bylaws
4:34pm
8-K
uq0xx1mdro5zfq00i
6 May 19
ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision
12:55pm
8-K
1n8 e2x94
2 May 19
Submission of Matters to a Vote of Security Holders
5:15pm
8-K
txg wu3x9
4 Apr 19
Termination of a Material Definitive Agreement
8:53pm
8-K
na7w1z
19 Mar 19
Entry into a Material Definitive Agreement
4:56pm
8-K
cgfsilpn4 hl6te
4 Mar 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:16pm
8-K
lh9 r9b5i10q
15 Jan 19
ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders
8:38pm
8-K
1ek6qpl2xjuj7g
2 Jan 19
Regulation FD Disclosure
4:26pm